What occurred when researchers took 1000’s of hashish samples representing 396 strain names to a laboratory? The analyzed samples turned out to be a whopping three distinct chemical varieties of hashish. From the evaluation, the scientists concluded that the strain name of a specific kind of hashish mainly doesn’t mean a lot of something in any respect. 

“The very limited variability in chemical profiles shows that most of these chemovars, while named differently, are almost the same or at least very similar,” the researchers wrote within the study, which appeared in Cannabis and Cannabinoid Research final month.

To carry out the examine, the researchers collected over 2,600 samples of hashish flower in Nevada between January 2016 and June 2017, when the state nonetheless solely had a medical marijuana program. They measured the chemical profiles by method of a third-party testing laboratory, which analyzed the cannabinoid and terpene content material in every pattern.Altogether, the researchers discovered that when analyzing the cannabinoid profiles, 93% of the samples may very well be grouped in the identical cluster (out of a complete of three clusters). Regarding terpenes, there have been three distinct clusters, representing 59%, 33%, and eight% of all samples. Each cluster had a particular, most ample terpene, both ?-myrcene, ?-terpinene, or limonene, respectively.

The researchers additionally took consultant DNA samples from every chemovar and located 12 distinct genetic clades.

“When analyzing the chemical testing data using a variety of statistical methods, we found that there was surprisingly little variability in the chemical profiles among the 2,662 dried flower samples,” the researchers acknowledged. Later within the report they acknowledged that when wanting on the cannabinoid composition, “except for the few high-CBD samples, all samples contained a very high amount of THC (>22% on average) and very small amounts of other cannabinoids.”

The researchers stated they assume that the terpene composition “is much more indicative of the sample’s origin and genetic background than the cannabinoid profile. The link between the terpenoids and the three clusters makes sense because the terpenes provide the colors and smells that differentiate the many varieties of cannabis.”

“The three chemovars and twelve genotypes reflect low medical diversity on the market in Nevada during its ‘medical use only’ phase. Furthermore, the 396 breeder-reported sample names within this set imply a false sense of diversity of products in Nevada dispensaries,” the researchers wrote of their conclusion.

The researchers outlined the shortage of standardization in hashish strain names, saying that they’re “poorly or not at all defined” and that this “creates a confusing situation for patients, who depend on the identifications and potency data on the packaging. If the commercial names bear little consistent relationship to either genotype or chemical phenotype, then they should not be the primary basis provided to patients for decision-making.”

They added that the shortage of correct labeling, inconsistent chemical profiles of marijuana merchandise, and restricted testing knowledge “make it difficult or impossible” for a lot of sufferers to acquire a constant chemical profile of the product.

The lab outcomes led the researchers to conclude that when creating new hashish chemovars, breeders primarily choose for prime THC ranges and that “all the other cannabinoids seem to have been mostly ignored in the breeding efforts, even though they have known or suspected specific medical values.”

If the names of hashish chemovars had been linked to the chemical signature of their lively components, medical doctors may make suggestions with higher confidence, the researchers wrote, including {that a} lack of affected person and doctor training on the medical advantages of different cannabinoids and terpenes could also be half of the rationale why high-THC strains dominate the market.

In a recent episode of the Cannabis Enigma podcast, hashish researcher Dr. Ethan Russo stated that the hashish business has targeted closely on producing high-THC strains which are additionally very excessive within the terpene myrcene, which has a sedating impact. This creates a scenario by which shoppers and medical marijuana sufferers aren’t in a position to really entry hashish that presents a variety of cannabinoids and terpenes.

“Part of this is a problem with breeding practices. The market is very much related to high-THC chemovars,” Russo stated, noting that the leisure market dwarfs the medical market lately.

Russo additionally acknowledged that the identify or the looks of the chemovar isn’t an correct method to actually grasp the make-up of the hashish in query.

“We have to know what’s in it, what are the predominant cannabinoids and terpenoids, and then we’d have a good idea of what to expect in terms of results or effects when people use that chemovar,” he stated.

This article was initially printed on The Cannigma and seems right here with permission. 

Source link